Abstract

Metastatic malignant struma ovarii (MMSO) is a very rare disease (in the United States, less than one case in 10 million females annually). However, this incidence rate is due to a paucity of data regarding diagnosis, treatment, and follow-up. Herein, we describe the case of a 14-year-old female who presented with MMSO, which later metastasized and was followed up on for over 10 years. The patient underwent right oophorectomy surgery and was then treated with a combination of radioactive iodine followed by iodine scans to detect the absorption of radioiodine in the metastatic sites, and radiation therapy to treat skeletal lesions. She subsequently received treatment with the tyrosine kinase inhibitors (TKIs), sorafenib and then lenvatinib, as treatments for advanced disease, thereby achieving long-term disease stability. This case report, which adds to the limited data available on MMSO treatment, suggests that patients treated with a combination of radioactive iodine, radiation therapy, and TKIs can result in good responses and long-term overall survival.

摘要

转移性恶性卵巢间质瘤 (MMSO) 是一种非常罕见的疾病（在美国，每年 1000 万女性中不到一例）。然而，这一发病率是由于缺乏有关诊断、治疗和随访的数据。在此，我们描述了一名 14 岁女性的 MMSO 病例，该病例后来转移并随访了 10 多年。该患者接受了右侧卵巢切除术，然后接受了放射性碘治疗，随后进行了碘扫描以检测转移部位的放射性碘吸收情况，以及用于治疗骨骼病变的放射治疗。随后，她接受了酪氨酸激酶抑制剂 (TKI)、索拉非尼和乐伐替尼的治疗，作为晚期疾病的治疗方法，从而实现了长期的疾病稳定性。这份病例报告，